Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease”.
Clinical Benefit
| Substantial |
Le service médical rendu par ATIMOS 12 microgrammes/dose, solution pour inhalation en flacon pressurisé est important.
|
Clinical Added Value
| no clinical added value |
ATIMOS 12 microgrammes/dose, solution pour inhalation en flacon pressurisé n'apporte pas d'amélioration du service médical rendu (ASMR V) par rapport aux autres bronchodilatateurs de longue durée d'action disponibles dans cette indication.
|
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
1DLtj6Whnn1HGRXu
